CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies
Cambridge, UK, and Durham, North Carolina, US - CN Bio and Altis Biosystems, Inc., leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, announces a strategic partnership.
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA
Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry.
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems
CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems
Cambridge, UK - CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), and LifeNet Health LifeSciences, “LifeNet Health”, a non-profit, global leader in all-human research solutions, announces a strategic partnership to supply validated primary human cells for use with CN Bio’s PhysioMimix® OOC range of MPS.
CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer
Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appoin
CN Bio appoints Dr. Samantha Macro as Chief Financial Officer
Key executive appointment provides extensive financial industry experience as the Company implements ambitious global growth strategy
CN Bio appoints Deepak Singh as Vice President of Sales and Marketing
Key appointment as company seeks to continue global expansion of microphysiological systems and contract research service offerings.
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
Cambridge, UK - CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), announces the commercial launch of the PhysioMimix™ Single-organ Higher Throughput (HT) System.
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S.
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and servicesCN Bio’s PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021’
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), has been recognised by The Scientist for developing a Top 10 Innovation of 2021. This year’s list includes CN Bio’s PhysioMimix™ Multi-Organ MPS; a next-generation OOC platform that provides advanced insights into the potential effects of novel therapeutics that…
CN Bio and iiCON announce COVID-19 research collaboration
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
CN Bio expands service offering to support oncology drug discovery
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
Lonza and CN Bio announce distribution agreement
Basel, Switzerland and Cambridge, UK...– Lonza and CN Bio have entered into a distribution agreement whereby Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in their PhysioMimixTM Single-and Multi-Organ MPS to transform the way human-relevant pre-clinical data is generated.
CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS.
FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the US Food and Drug Administration (FDA) has extended their research collaboration for a further three years.
CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), has announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
CN Bio’s PhysioMimix technology receives FDA recognition
CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the US Food and Drug Administration (FDA)1.
CN Bio and University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
CN Bio to provide drug metabolism and safety toxicity testing services
CN Bio, a leading 3D cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.
CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, has announced a collaboration with Imperial College London, a world-class research university. The research will harness CN Bio’s Liver-on-Chip technology to advance the understanding of the underlying mechanisms of alcoholic…